TY - JOUR
T1 - The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
AU - Focosi, Daniele
AU - Farrugia, Albert
PY - 2021/1
Y1 - 2021/1
N2 - COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide suggestions for the next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.
AB - COVID-19 convalescent plasma (CCP) is widely used as a treatment. Although there are sufficient safety data, high-level evidence of efficacy is still lacking. We summarize here the results from randomized controlled trials (RCTs) published to date and analyze their flaws and biases. We then provide suggestions for the next round of CCP RCTs, discussing specification of CCP, therapeutic dose, timing, control arm, disease stage, and outcome measures.
KW - Convalescent plasma
KW - COVID19
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85096859374&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2020.10.074
DO - 10.1016/j.ijid.2020.10.074
M3 - Article
C2 - 33130197
AN - SCOPUS:85096859374
SN - 1201-9712
VL - 102
SP - 244
EP - 246
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
ER -
